Vasculitis News and Research

Latest Vasculitis News and Research

Psychological stress can trigger flares of vasculitis

Psychological stress can trigger flares of vasculitis

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

HealthWell Foundation introduces new lupus fund

HealthWell Foundation introduces new lupus fund

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

UTHealth inaugurates new center for autoimmune and inflammatory diseases research

SQI Diagnostics third quarter net loss increases to $2,691,000

SQI Diagnostics third quarter net loss increases to $2,691,000

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada grants Vasculitis and Scleroderma Fellowship

Contaminated cocaine may lead to public health epidemic

Contaminated cocaine may lead to public health epidemic

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

SQI Diagnostics reports net loss of $1,874,000 for second quarter 2011

SQI Diagnostics reports net loss of $1,874,000 for second quarter 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

Health Canada grants SQI license to market IgX PLEX Celiac Panel

Health Canada grants SQI license to market IgX PLEX Celiac Panel

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics first quarter net loss increases to $2,255,000